For health systems
CMIOs, chief AI officers, service-line directors and value-analysis committees make purchasing and governance decisions about cardiovascular AI. When tools become billable, hospitals need structured, independent purchasing evidence.
- A complete, standardized, evidence-graded directory of authorized cardiovascular AI, including cardiac tools reviewed under other FDA panels
- A condition-by-condition map of where AI fits in the patient journey and where evidence is thin
- Support for technology assessment, governance and implementation strategy